Clinicopathological significance of hyaluronan and hyaluronidase 2 (HYAL2) in breast cancer
Pathology - Research and Practice · 2024
DOI: 10.1016/j.prp.2024.155434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Shiori Fujisawa und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan; Department of Pa…. Hauptthemen laut MEDLINE: Hyaluronoglucosaminidase, Breast Neoplasms, Hyaluronic Acid, Cell Proliferation. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
Hyaluronan (HA), as a component of extracellular matrix, has pivotal roles in both physiological and pathological condition. In breast cancer, while high molecular weight HA is produced by hyaluronan synthase, it is degraded by hyaluronidases (hyaluronidase-1 (HYAL1) and hyaluronidase-2 (HYAL2)) into low molecular weight HA (LMW HA), which is considered to have pro-tumorigenic effects in human malignancies. However, HA and HYAL2, the rate-limiting enzyme of HA degradation, have not been comprehensively examined in breast cancer and clinicopathological significance of LMW HA remains to be elucidated in breast cancer. We therefore histochemically localized HA as well as HYAL2 in 116 breast cancer tissues. In addition, we examined size-dependent function of HA on breast cancer cell proliferation and migration using MCF-7 and MDA-MB-231 breast cancer cell lines. HA was localized in both the stroma and breast carcinoma cells, while HYAL2 was predominantly localized in breast carcinoma cells. HA was significantly correlated with cell proliferation and invasion ability as well as increased risk of recurrence especially in HYAL2 positive group. On the other hand, HYAL2 was correlated with breast cancer cell proliferation and increased risk of recurrence. In addition, in vitro analyses revealed that lower molecular weight HA increased sphere forming ability and migration in MCF-7 and MDA-MB-231, whereas higher molecular weight HA inhibited them. It was concluded that HA needs to be degraded by HYAL2 to exert pro-tumorigenic effects and comprehensive HA/HYAL2 status serves as a potent prognostic factor in breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan; Department of Pathology and Histotechnology, Tohoku University Graduate School of Medi…
- Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan. Electronic address: kiyoshi.takagi.b7@tohoku.ac.jp.
- Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan; Department of Personalized Medicine Center and Tohoku University Hospital, Sendai, Miyagi 980-8…
- Department of Pathology and Histotechnology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan.
- Department of Anatomic Pathology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan.
- Department of Breast and Endocrine Surgical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi 980-8575, Japan.
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Fujisawa, S., Takagi, K., Yamaguchi-Tanaka, M., Sato, A., Miki, Y., Miyashita, M., Tada, H., Ishida, T., & Suzuki, T. (2024). Clinicopathological significance of hyaluronan and hyaluronidase 2 (HYAL2) in breast cancer. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155434
Vancouver
Fujisawa S, Takagi K, Yamaguchi-Tanaka M, Sato A, Miki Y, Miyashita M, et al. Clinicopathological significance of hyaluronan and hyaluronidase 2 (HYAL2) in breast cancer. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155434
BibTeX
@article{Fujisawa2024,
author = {Fujisawa, Shiori and Takagi, Kiyoshi and Yamaguchi-Tanaka, Mio and Sato, Ai and Miki, Yasuhiro and Miyashita, Minoru and Tada, Hiroshi and Ishida, Takanori and Suzuki, Takashi},
title = {Clinicopathological significance of hyaluronan and hyaluronidase 2 (HYAL2) in breast cancer},
journal = {Pathology - Research and Practice},
year = {2024},
doi = {10.1016/j.prp.2024.155434}
}
EUVIMED